Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Study period:
12 June to 03 July 2014
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
GLP study conducted according to OECD Guideline 402 without deviation.

Data source

Reference Type:
study report
Report date:

Materials and methods

Test guidelineopen allclose all
according to guideline
OECD Guideline 402 (Acute Dermal Toxicity)
according to guideline
EU Method B.3 (Acute Toxicity (Dermal))
Principles of method if other than guideline:
Not applicable
GLP compliance:
yes (incl. QA statement)
UK GLP Compliance Programme (inspected on 12-14 March 2014 / signed on 12 May 2014)
Test type:
standard acute method
Limit test:

Test material

Constituent 1
Chemical structure
Reference substance name:
EC Number:
Cas Number:
Molecular formula:
Test material form:
Details on test material:
- Physical state: Colourless liquid
- Water solubility: 2.16 g/L
- Vapour pressure: 0.33 Pa (at 20°C) and 0.59 Pa (at 25°C)
- Partition coefficient: 2.69 (HPLC, 2013)
- Storage Conditions: 6 ± 2 °C, protected from light, under nitrogen in the original container
- Stability under test conditions: Not specified, assumed to be stable
Specific details on test material used for the study:
- Purity test date: 30 October 2013
- Storage Conditions: Stored at room temperature in the dark

Test animals

RccHan™: WIST strain
Details on test animals or test system and environmental conditions:
- Source: Harlan Laboratories UK Limited, Bicester, Oxon, UK.
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 249-289 g (males); 210-222 g (females)
- Housing: Animals were housed in suspended solid-floor polypropylene cages furnished with woodflakes. Animals were housed individually during the 24 h exposure period and in groups of five by sex for the remainder of the study.
- Diet: Food (2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK), ad libitum
- Water: Mains drinking water, ad libitum
- Acclimation period: 5 days

- Temperature: 19-25 °C
- Humidity: 30-70 %
- Air changes: 15 changes per hour
- Photoperiod: 12 h dark / 12 h light

IN-LIFE DATES: 12 June to 03 July 2014

Administration / exposure

Type of coverage:
unchanged (no vehicle)
Details on dermal exposure:
- Pretreatment: On the day before treatment the back and flanks of each animal were clipped free of hair.
- Area of exposure: Back and flank area
- % coverage: Approximately 10 % of the total body surface area.
- Application of test item: Test item was used as supplied. The test item was applied as evenly as possible to an area of shorn skin (approximately 10 % of the total body surface area) using a graduated syringe.
- Type of wrap if used: A piece of surgical gauze was placed over the treatment area and semi-occluded with a piece of self-adhesive bandage.

- Washing: After the 24 h contact period, the bandage was carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with arachis oil BP to remove any residual test substance.
- Time after start of exposure: 24 h

- For the purpose of the study the test item was used as supplied. The specific gravity was determined (1.100) and used to calculate the appropriate dose volume for the required dose level.
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- Constant volume or concentration used: Yes; 1.82 mL/kg bw
Duration of exposure:
24 h
2000 mg/kg bw
No. of animals per sex per dose:
Control animals:
not required
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations: Animals were observed for mortality or clinical signs of toxicity at 0.5, 1, 2 and 4 h after dosing and subsequently once daily for 14 days. After removal of the dressings and subsequently once daily for fourteen days, the test sites were examined for evidence of primary irritation and scored according to Draize scale.
- Frequency of weighing: Individual bodyweights were recorded prior to application of the test substance on Day 0 and on Days 7 and 14.
- Necropsy of survivors performed: Yes; at the end of the study animals were killed by cervical dislocation and subjected to gross necropsy.

Results and discussion

Preliminary study:
Not applicable
Effect levels
Key result
Dose descriptor:
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: no mortality was observed
No mortality was observed.
Clinical signs:
other: - No signs of systemic toxicity were noted during the observation period. - Very slight erythema and crust formation were noted at the test sites of two females. Glossy skin was also noted at the test site of one of these females. There were no signs of d
Gross pathology:
No abnormalities were noted at necropsy.
Other findings:

Any other information on results incl. tables


Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Under the test conditions, the dermal LD50 of the test substance is higher than 2000 mg/kg bw in rats therefore it is not classified for acute dermal toxicity according to the criteria of the Annex VI of the Regulation (EC) N°1272/2008 (CLP) and to the GHS since there is no reliable evidence that indicates the LD50 to be in the range of Category 5 values.
Executive summary:

An acute dermal toxicity study (limit test) performed according to OECD Guideline No. 402 and in compliance with GLP. Initially, two animals (one male and one female) were given a single, 24 hour, semi-occluded dermal application of the undiluted test item to intact skin at a dose level of 2000 mg/kg bw. Based on the results of the initial test, a further group of eight animals (four males and four females) was similarly treated. Test sites were covered with a semi-occlusive dressing for 24 h. Animals were observed for mortality, clinical signs and bodyweights for 14 days and at the end of the study the surviving animals were sacrificed for macroscopic examination.


There were no deaths or signs of systemic toxicity. Very slight erythema, glossy skin and/or crust formation were noted at the test sites of two females. There were no signs of dermal irritation noted at the test sites of all males and three females. Animals showed expected gains in body weight, except for one female which showed no gain in body weight during the first week with expected gain in body weight during the second week. However, this was still considered to be within the historical range for this strain. No abnormalities were noted at necropsy.


Dermal LD50 Combined > 2000 mg/kg bw.


Under the test conditions, the test substance is not classified according to the Annex VI of Regulation (EC) No. 1272/2008 (CLP) and to the GHS.

This study is considered as acceptable and satisfies the requirement for acute dermal toxicity endpoint.